Clinical Trial: Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07168902) titled 'Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension' on Sept. 05.

Brief Summary: Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults with Primary Open Angle Glaucoma or Ocular Hypertension

Study Start Date: Oct., 2025

Study Type: INTERVENTIONAL

Condition: Glaucoma

Intervention: DRUG: BL1107 Low dose

Dosed twice daily for 28 days.

DRUG: BL1107 High dose

Dosed twice daily for 28 days.

DRUG: Timolol maleate 0.5%

Dosed twice daily for 28 days.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Bausch & Lomb Incorporated

Disclaimer: Curated by HT Syndication....